1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Shanghai Yizhong Pharmaceutical Co., Ltd.

Shanghai Yizhong Pharmaceutical Co., Ltd.

688091.SS
Shanghai Yizhong Pharmaceutical Co., Ltd.CN flagShanghai Stock Exchange
48.11
CNY
+3.68
- -
9.94BMarket Cap
Shanghai Yizhong Pharmaceutical Co., Ltd.
688091.SS
(Shanghai Stock Exchange)

Recent

price

48.11

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
0.04
1.26
2.27
0.75
1.57
1.05
Revenue per Share
-0.08
-0.09
-2.26
-0.14
-0.03
0.76
1.02
0.03
0.32
0.05
Basic EPS, GAAP
-0.1
-0.1
-0.51
-0.17
-0.45
0.4
0.49
-0.17
-0.74
-0.69
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.01
- -
0.27
0.21
- -
- -
Dividend per Share
0.32
0.23
-1.97
0.37
0.69
1.32
2.31
1.59
2.12
2.02
Book Value per Share
1.44
1.5
1.83
1.54
10.2
6.99
9.19
6.01
6.95
7.1
Tangible Book Value per Share
130
136
140
152
114
188
158
233
202
203
Basic Weighted Avg Shares
- -
- -
- -
- -
4
236
360
174
316
212
Sales/Revenue/Turnover
- -
- -
- -
- -
-498.01
51.88
46.21
-11.39
15.81
-5.68
Operating Margin (%)
4
5
5
6
7
6
8
11
12
- -
Depreciation Expense
-10
-13
-315
-22
-4
143
162
7
65
10
Net Income, GAAP
- -
- -
- -
- -
- -
4.48
13.56
- -
- -
11.89
Effective Tax Rate (%)
- -
- -
- -
- -
-98.03
60.54
44.84
4.02
20.42
4.94
Profit Margin (%)
93
156
130
46
972
1,170
1,309
737
562
703
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
25
- -
LT Debt
198
213
265
244
1,176
1,319
1,465
1,405
1,430
1,447
Total Equity
- -
- -
- -
- -
- -
9.31
10.15
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
82.92
49.2
- -
- -
0.75
Return on Capital (%)
- -
-34.35
- -
- -
-5.88
87.17
52.65
1.9
16.16
2.6
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
207
207
207
Market Capitalization
6,471
8,305
9,480

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
776
773
746
Cash, Cash Equivalents & STI
644
611
544
Accounts Receivable, Net
45
53
97
Inventories
45
50
58
Total Current Liabilities
39
41
44
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
80.75%
1.8%
Free Cash Flow
- -
-3.7%
268.17%
Net Income, GAAP
- -
-602.56%
825.49%
Sales/Revenue/Turnover
- -
- -
82.14%
Total Cash Common Dividend
- -
- -
-99.85%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
69
53
48
4
174
2025
71
89
73
- -
316
2026
79
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.18
- -
- -
- -
0.03
2025
0.07
- -
- -
- -
0.32
2026
0.09
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.21
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Dynavax Technologies Corporation (0IDA.L)
Beijing Tongrentang Co., Ltd (600085.SS)
Selçuk Ecza Deposu Ticaret ve Sanayi A.S. (SELEC.IS)
Impax Laboratories, Inc. (IPXL)
Santhera Pharmaceuticals Holding AG (SPHDF)
Burzynski Research Institute, Inc. (BZYR)
Business
Shanghai Yizhong Pharmaceutical Co., Ltd. focuses on the research, development, and commercialization of anti-tumor drugs and related therapeutic solutions across China. The company's primary product is injectable paclitaxel polymeric micelles, a notable chemotherapy agent that was recently integrated into the national medical insurance catalog. Shanghai Yizhong Pharmaceutical commenced its operations in 2009 and is headquartered in Shanghai, China.